Search Back New search Go to resultsDiseaseMain groupPediatric Oncology and HematologyProtocol groupRare Diseases (ped.)DiseaseNeurofibromatosisSubgroupPlexiform Neurofibromatype 1ICD10Q85.0MeSHSequenceChemotherapyChemo-substanceSelumetinibChemo-substanceSelumetinibChemo-substanceSelumetinibChemo-substanceSelumetinibNo. Substances1 RadiotherapySupportive therapySupportive substanceSupportive substanceSupportive substanceSupportive substanceNo. SubstancesProtocol classificationTherapy classificationcurrent standardIntensityTherapy indicationseveral possibleTherapy phaseTherapy intentiondisease controlRisksAnemia Hb below 8g/dlCardiotoxicityConstipationDiarrheaEmetogenicityHypocalcemiaIncrease AminotransferasesIncrease Creatinine PhosphokinaseMucositisNail ChangesNeutropeniaPruritusPyrexiaRashRenal FailureThrombocytopenia below 50 000/µl only studiesPublicationAuthorGross AMDiseaseNeurofibromatose Typ 1, Plexiforme Neurofibrome nicht operabel, <18 JahreOriginNational Institutes of Health, BethesdaProtocols in Revision 1 protocol foundProtocols under revision.Selumetinib 25, neurofibromatosis (PID2226 V1.0)
